An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung: a southwest oncology group study

Terence N. Moore, Robert B Livingston, Lance Heilbrun, Fred Y. Durrance, Donald Tesh, Bernard Hickman, Carl Bogardus

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In the past few years, many reports have appeared in the literature regarding combination chemotherapy and irradiation in patients with carcinoma. Many reports have concentrated on the complications of such therapy. In 1974, the Southwest Oncology Group undertook a protocol combining chemotherapy (doxorubicin, cyclophosphamide and vincristine) with radiation therapy to the brain and the primary tumor in a sandwich fashion. Of concern in the past was the enhancement of radiation reactions when chemotherapy and irradiation were combined. We have studied the incidence of complications and found them to be within an acceptable range (esophageal, 5%; pulmonary, 2.7%; epithelial, less then 1%). Therefore, we present a treatment regimen which has demonstrated an increase in longevity combined with an acceptable complication rate-the result of careful planning by oncologists of the modalities involved.

Original languageEnglish (US)
Pages (from-to)675-680
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume4
Issue number7-8
DOIs
StatePublished - 1978
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
chemotherapy
Doxorubicin
lungs
cancer
Drug Therapy
irradiation
Vincristine
Combination Drug Therapy
Brain Neoplasms
Cyclophosphamide
Radiotherapy
Radiation
Carcinoma
Lung
brain
planning
radiation therapy
therapy
Incidence

Keywords

  • Complications
  • Doxorubicin
  • Irradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung : a southwest oncology group study. / Moore, Terence N.; Livingston, Robert B; Heilbrun, Lance; Durrance, Fred Y.; Tesh, Donald; Hickman, Bernard; Bogardus, Carl.

In: International Journal of Radiation Oncology Biology Physics, Vol. 4, No. 7-8, 1978, p. 675-680.

Research output: Contribution to journalArticle

Moore, Terence N. ; Livingston, Robert B ; Heilbrun, Lance ; Durrance, Fred Y. ; Tesh, Donald ; Hickman, Bernard ; Bogardus, Carl. / An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung : a southwest oncology group study. In: International Journal of Radiation Oncology Biology Physics. 1978 ; Vol. 4, No. 7-8. pp. 675-680.
@article{d1d148a49cf540e68c9556652f28f76f,
title = "An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung: a southwest oncology group study",
abstract = "In the past few years, many reports have appeared in the literature regarding combination chemotherapy and irradiation in patients with carcinoma. Many reports have concentrated on the complications of such therapy. In 1974, the Southwest Oncology Group undertook a protocol combining chemotherapy (doxorubicin, cyclophosphamide and vincristine) with radiation therapy to the brain and the primary tumor in a sandwich fashion. Of concern in the past was the enhancement of radiation reactions when chemotherapy and irradiation were combined. We have studied the incidence of complications and found them to be within an acceptable range (esophageal, 5{\%}; pulmonary, 2.7{\%}; epithelial, less then 1{\%}). Therefore, we present a treatment regimen which has demonstrated an increase in longevity combined with an acceptable complication rate-the result of careful planning by oncologists of the modalities involved.",
keywords = "Complications, Doxorubicin, Irradiation",
author = "Moore, {Terence N.} and Livingston, {Robert B} and Lance Heilbrun and Durrance, {Fred Y.} and Donald Tesh and Bernard Hickman and Carl Bogardus",
year = "1978",
doi = "10.1016/0360-3016(78)90192-X",
language = "English (US)",
volume = "4",
pages = "675--680",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "7-8",

}

TY - JOUR

T1 - An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung

T2 - a southwest oncology group study

AU - Moore, Terence N.

AU - Livingston, Robert B

AU - Heilbrun, Lance

AU - Durrance, Fred Y.

AU - Tesh, Donald

AU - Hickman, Bernard

AU - Bogardus, Carl

PY - 1978

Y1 - 1978

N2 - In the past few years, many reports have appeared in the literature regarding combination chemotherapy and irradiation in patients with carcinoma. Many reports have concentrated on the complications of such therapy. In 1974, the Southwest Oncology Group undertook a protocol combining chemotherapy (doxorubicin, cyclophosphamide and vincristine) with radiation therapy to the brain and the primary tumor in a sandwich fashion. Of concern in the past was the enhancement of radiation reactions when chemotherapy and irradiation were combined. We have studied the incidence of complications and found them to be within an acceptable range (esophageal, 5%; pulmonary, 2.7%; epithelial, less then 1%). Therefore, we present a treatment regimen which has demonstrated an increase in longevity combined with an acceptable complication rate-the result of careful planning by oncologists of the modalities involved.

AB - In the past few years, many reports have appeared in the literature regarding combination chemotherapy and irradiation in patients with carcinoma. Many reports have concentrated on the complications of such therapy. In 1974, the Southwest Oncology Group undertook a protocol combining chemotherapy (doxorubicin, cyclophosphamide and vincristine) with radiation therapy to the brain and the primary tumor in a sandwich fashion. Of concern in the past was the enhancement of radiation reactions when chemotherapy and irradiation were combined. We have studied the incidence of complications and found them to be within an acceptable range (esophageal, 5%; pulmonary, 2.7%; epithelial, less then 1%). Therefore, we present a treatment regimen which has demonstrated an increase in longevity combined with an acceptable complication rate-the result of careful planning by oncologists of the modalities involved.

KW - Complications

KW - Doxorubicin

KW - Irradiation

UR - http://www.scopus.com/inward/record.url?scp=0018166331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018166331&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(78)90192-X

DO - 10.1016/0360-3016(78)90192-X

M3 - Article

C2 - 213407

AN - SCOPUS:0018166331

VL - 4

SP - 675

EP - 680

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 7-8

ER -